BIOMARKERS

The TIMI Biomarker Program, established in 1996, has now conducted more than 40 nested biomarker studies across our multicenter trials. These studies range from smaller mechanistic substudies to large multinational population analyses up to 25,000 subjects, including registration pathway studies. The TIMI Biomarker Program has more than 500,000 samples collected and stored. The program is a world leader in broad-based biomarker testing, including traditional candidate proteins, platelet function measures, and proteomic, transcriptomic, and metabolomic discovery methods.

Areas of Focus

  • Evaluation of novel markers of ischemia, injury, inflammation, hemodynamic stress, & thrombosis
  • Diagnosis
  • Risk Assessment
  • Therapeutic monitoring
  • Value added to present biomarkers
  • Investigation of interactions between individual biomarkers and specific therapies with aim of enhanced therapeutic decision-making
  • Development of multi-marker approaches to risk assessment and clinical decision-making
  • Discovery of novel biomarkers using proteomics, transcriptomic, and metabolomic approaches

Key Program Contributions

  • Established prognostic use of cardiac troponin I (cTnI) in NSTE ACS
  • Key data --> FDA approval of risk stratification indication for 3 cTnI assays
  • Demonstrate the association of hs-CRP with mortality in troponin-negative patients
  • First to demonstrate prognostic value of B-type natriuretic peptide (BNP) in NSTE ACS
  • Established the value of low-level elevation of troponin for selection of patients for early invasive management
  • 1st report of the combined value of cardiac troponin, high-sensitivity C-reactive protein, and B-type natriuretic peptide in a multi-marker approach to risk assessment
  • 1st to demonstrate elevation of ultrasensitive cardiac troponin in patients with provoked ischemia during exercise testing